Theriva Biologics (NYSEAMERICAN:TOVX) Shares Up 3.8% – Here’s Why

Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shot up 3.8% on Thursday . The stock traded as high as $0.2621 and last traded at $0.2525. 1,535,853 shares changed hands during mid-day trading, an increase of 188% from the average daily volume of 532,729 shares. The stock had previously closed at $0.2432.

Theriva Biologics Price Performance

The stock has a market cap of $8.52 million, a P/E ratio of -0.01 and a beta of 1.11. The business has a 50 day simple moving average of $0.23 and a 200-day simple moving average of $0.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.13 and a current ratio of 1.13.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its earnings results on Tuesday, August 11th. The company reported ($0.07) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned 0.64% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is owned by institutional investors.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.